Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADXNNASDAQ:AIMDNASDAQ:AYTUNASDAQ:PCSA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXNAddex Therapeutics$7.99-2.6%$7.66$6.51▼$13.27$8.47M1.6293,875 shs3,057 shsAIMDAinos$0.75+23.5%$0.54$0.40▼$1.17$12.60M2.14517,230 shs1.66 million shsAYTUAytu BioPharma$1.91-3.5%$1.33$0.95▼$3.23$11.79M-0.1322,838 shs135,925 shsPCSAProcessa Pharmaceuticals$0.30+12.5%$0.27$0.15▼$3.10$3.57M1.361.11 million shs2.57 million shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXNAddex Therapeutics-6.61%-2.80%+6.30%-5.95%-6.39%AIMDAinos+22.93%+54.81%+39.91%+34.63%-25.75%AYTUAytu BioPharma-3.54%-5.45%+76.04%+52.80%-39.37%PCSAProcessa Pharmaceuticals+12.48%+24.51%+27.58%-44.28%-82.94%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADXNAddex Therapeutics2.7011 of 5 stars3.55.00.00.03.30.80.0AIMDAinos0.4588 of 5 stars0.02.00.00.02.40.80.6AYTUAytu BioPharma1.3035 of 5 stars0.02.00.03.43.01.70.6PCSAProcessa Pharmaceuticals2.4074 of 5 stars3.52.00.00.01.81.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADXNAddex Therapeutics 3.00Buy$30.00275.28% UpsideAIMDAinos 0.00N/AN/AN/AAYTUAytu BioPharma 0.00N/AN/AN/APCSAProcessa Pharmaceuticals 3.00Buy$6.001,898.67% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADXNAddex Therapeutics$404.10K20.97N/AN/A$1.20 per share6.66AIMDAinos$106.21K146.61N/AN/A$5.23 per share0.14AYTUAytu BioPharma$81.66M0.14N/AN/A$4.64 per share0.41PCSAProcessa PharmaceuticalsN/AN/AN/AN/A$4.05 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADXNAddex Therapeutics-$11.76M-$0.34N/A∞N/A850.30%-112.43%-77.95%6/2/2025 (Estimated)AIMDAinos-$13.77M-$1.29N/A∞N/AN/A-75.16%-50.22%8/4/2025 (Estimated)AYTUAytu BioPharma-$15.84M-$0.72N/A∞N/A-7.62%-19.30%-4.80%N/APCSAProcessa Pharmaceuticals-$11.12M-$3.08N/AN/AN/AN/A-195.21%-163.06%8/12/2025 (Estimated)Latest PCSA, ADXN, AIMD, and AYTU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/2/2025Q1 2025ADXNAddex Therapeutics-$1.4197N/AN/AN/AN/AN/A5/14/2025Q3 2025AYTUAytu BioPharma-$0.17$0.20+$0.37$0.21$13.74 million$18.45 million5/12/2025Q1 2025AIMDAinosN/A-$0.21N/A-$0.21N/A$0.11 million5/8/2025Q1 2025PCSAProcessa Pharmaceuticals-$0.77-$0.30+$0.47-$0.30N/AN/A3/20/2025Q4 2024PCSAProcessa Pharmaceuticals-$0.92-$0.74+$0.18-$0.74N/AN/A3/7/2025Q4 2024AIMDAinosN/A-$0.26N/A-$0.26N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADXNAddex TherapeuticsN/AN/AN/AN/AN/AAIMDAinosN/AN/AN/AN/AN/AAYTUAytu BioPharmaN/AN/AN/AN/AN/APCSAProcessa PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADXNAddex TherapeuticsN/A4.594.59AIMDAinos0.501.371.33AYTUAytu BioPharma0.320.980.81PCSAProcessa PharmaceuticalsN/A3.973.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADXNAddex Therapeutics16.14%AIMDAinosN/AAYTUAytu BioPharma33.49%PCSAProcessa Pharmaceuticals91.93%Insider OwnershipCompanyInsider OwnershipADXNAddex Therapeutics15.00%AIMDAinos10.39%AYTUAytu BioPharma3.60%PCSAProcessa Pharmaceuticals9.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADXNAddex Therapeutics301.06 million901,000Not OptionableAIMDAinos4020.76 million12.62 millionNot OptionableAYTUAytu BioPharma1606.17 million6.00 millionNot OptionablePCSAProcessa Pharmaceuticals2011.88 million2.84 millionNot OptionablePCSA, ADXN, AIMD, and AYTU HeadlinesRecent News About These CompaniesProcessa Pharmaceuticals (NASDAQ:PCSA) Stock Price Down 1.5% - What's Next?May 24, 2025 | americanbankingnews.comProcessa Pharmaceuticals’ Dr. David Young to Present at World Orphan Drug Congress USA 2025April 15, 2025 | markets.businessinsider.comProcessa Pharmaceuticals' Dr. David Young to Present at World Orphan Drug Congress USA 2025April 15, 2025 | globenewswire.comProcessa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor ConferenceMarch 18, 2025 | globenewswire.comProcessa Pharmaceuticals, Inc. (PCSA): Among the Cheapest Stocks Insiders Are Buying RecentlyFebruary 21, 2025 | insidermonkey.comProcessa Pharmaceuticals faces Nasdaq delisting risk over share priceFebruary 10, 2025 | msn.comFavourable Signals For Processa Pharmaceuticals: Numerous Insiders Acquired StockFebruary 7, 2025 | finance.yahoo.comProcessa Pharmaceuticals to Present at the 2025 BIO CEO & Investor ConferenceFebruary 7, 2025 | globenewswire.comProcessa Pharmaceuticals Closes $5 Million Public Offering with CEO and Institutional Investor ParticipationJanuary 30, 2025 | quiverquant.comProcessa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq RulesJanuary 30, 2025 | globenewswire.comProcessa Pharmaceuticals director David Young buys $99,288 in stockJanuary 30, 2025 | msn.comProcessa Pharmaceuticals' chief business officer buys $34,691 in stockJanuary 30, 2025 | msn.comInsider Buying: Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) CEO Acquires 87,200 Shares of StockJanuary 30, 2025 | insidertrades.comProcessa Pharmaceuticals prices $5M at-the-market offeringJanuary 29, 2025 | markets.businessinsider.comProcessa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq RulesJanuary 27, 2025 | globenewswire.comProcessa Pharmaceuticals stock hits 52-week low at $0.65January 27, 2025 | msn.comProcessa Pharmaceuticals stock hits 52-week low at $0.8January 17, 2025 | msn.comProcessa Pharmaceuticals files to sell common stock, no amount givenDecember 21, 2024 | markets.businessinsider.comProcessa Pharmaceuticals files to sell common stock, no amount givenDecember 21, 2024 | markets.businessinsider.comWhy Is Processa Pharmaceuticals Inc (PCSA) Stock Surpassing 13.85% from Its 50-Day SMA?December 11, 2024 | bovnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePCSA, ADXN, AIMD, and AYTU Company DescriptionsAddex Therapeutics NASDAQ:ADXN$7.99 -0.22 (-2.63%) Closing price 05/28/2025 03:56 PM EasternExtended Trading$8.08 +0.09 (+1.06%) As of 05/28/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.Ainos NASDAQ:AIMD$0.75 +0.14 (+23.54%) As of 05/28/2025 04:00 PM EasternAinos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.Aytu BioPharma NASDAQ:AYTU$1.91 -0.07 (-3.54%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$1.90 0.00 (-0.26%) As of 05/28/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.Processa Pharmaceuticals NASDAQ:PCSA$0.30 +0.03 (+12.48%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$0.30 0.00 (-0.73%) As of 05/28/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Amer Sports: The New ONON and DECK of Consumer Discretionary? BigBear.ai: Risky AI Stock or Defense Tech Opportunity? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
